Technology Prognosis: Luxturna (Voretigene Neparvovec-rzyl)
Share
Share
Proposed Use Gene therapy for treatment of vision loss due to RPE65 gene mutation
Regulatory Status Phase I/II Trials Complete Phase III Trials in Progress Phase III Trials Published FDA Filing Complete FDA Approved
Estimated Commercial Availability Unable to Determine >2 years 1 to 2 years <6 months Currently Available

Check out this technology prognosis to learn more.

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies.
Thanks for signing up. You must confirm your email address before we can send you. Please check your email and follow the instructions.
×
×